Checkpoint inhibitors can hinder CD47’s interaction with checkpoint receptors like programmed death-1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), bolstering anti-tumor immunity and potentially enhancing clinical outcomes in cancer patients [66]. The gene discussed is HAVCR2; the disease is cancer.